Author:
Reuters
article author:
ID:
1599728622398748300
Thu, 2020-09-10 08:49
LONDON: AstraZeneca’s chief executive Pascal Soriot said on Thursday that it should know before the end of the year whether its experimental vaccine would protect people from COVID-19, if the British drugmaker is allowed to resume trials which were paused this week.
It suspended the late-stage trials after an illness in a study subject in Britain. The patient was reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

Main category:
Tags: